BioSig Calls Special Shareholder Meeting for Sept 5

TL;DR

**STEX is holding a special shareholder meeting on September 5th, so get your proxy votes in to avoid missing out on key decisions.**

AI Summary

BioSig Technologies, Inc. (STEX) has filed a Definitive Proxy Statement (DEF 14A) on August 4, 2025, for a Special Meeting of Stockholders to be held virtually on September 5, 2025, at 10:00 a.m. Eastern Time. The filing, signed by CEO Henry McPhie, primarily serves to notify shareholders of the upcoming meeting and solicit their votes. While specific financial figures for revenue or net income are not detailed within this particular DEF 14A, the document emphasizes the importance of shareholder participation to ensure a quorum. Shareholders are encouraged to vote via the Internet, telephone, or by returning a proxy card, with instructions provided for those whose shares are held by a broker or nominee. The company's business address is 12424 Wilshire Blvd., Suite 745, Los Angeles, CA 90025, and its phone number is (203) 409-5444. The strategic outlook, based on this filing, is focused on corporate governance and ensuring shareholder engagement for upcoming decisions, rather than immediate operational or financial changes.

Why It Matters

This DEF 14A filing signals BioSig Technologies' commitment to corporate governance and shareholder engagement, which is crucial for maintaining investor confidence. For investors, it means an opportunity to exercise their voting rights on undisclosed matters, potentially influencing the company's future direction. Employees and customers might see this as a routine procedural step, but the outcomes of the Special Meeting could indirectly impact strategic initiatives or resource allocation. In the competitive electromedical and electrotherapeutic apparatus sector, transparent governance is a key differentiator, and this meeting ensures BioSig adheres to regulatory standards.

Risk Assessment

Risk Level: low — The risk level is low because this DEF 14A is a routine procedural filing for a Special Meeting of Stockholders, primarily focused on soliciting votes and ensuring a quorum. It does not disclose any immediate adverse financial or operational changes, nor does it indicate any significant new risks to the company's business model or financial health. The filing simply outlines the logistics for shareholder participation.

Analyst Insight

Investors should promptly review the full proxy materials available at www.proxyvote.com to understand the specific proposals to be voted on at the September 5, 2025, Special Meeting. Vote your shares via internet, telephone, or proxy card to ensure your voice is heard and to contribute to quorum requirements.

Key Numbers

• September 5, 2025 — Special Meeting Date (Date shareholders are invited to attend the virtual meeting)
• 10:00 a.m. ET — Meeting Time (Specific time the virtual Special Meeting will commence)
• August 4, 2025 — Filing Date (Date the Definitive Proxy Statement was filed with the SEC)
• 1 — Number of Filings (This is a single DEF 14A filing)
• 001-38659 — SEC File Number (Unique identifier for BioSig Technologies' SEC filings)

Key Players & Entities

• BioSig Technologies, Inc. (company) — Registrant filing the DEF 14A
• Henry McPhie (person) — Chief Executive Officer of BioSig Technologies, Inc.
• SEC (regulator) — United States Securities and Exchange Commission
• September 5, 2025 (date) — Date of the Special Meeting of Stockholders
• August 4, 2025 (date) — Filing date of the DEF 14A
• 10:00 a.m. Eastern Time (time) — Start time of the Special Meeting
• 12424 Wilshire Blvd., Suite 745, Los Angeles, CA 90025 (address) — Business address of BioSig Technologies, Inc.
• (203) 409-5444 (phone_number) — Business phone number of BioSig Technologies, Inc.
• 001-38659 (identifier) — SEC File Number for BioSig Technologies, Inc.
• 0001530766 (identifier) — Central Index Key (CIK) for BioSig Technologies, Inc.

FAQ

Industry Context

BioSig Technologies, Inc. operates in the electromedical and electrotherapeutic apparatus sector. This industry is characterized by rapid technological advancements, stringent regulatory oversight from bodies like the FDA, and a competitive landscape driven by innovation in medical devices and diagnostic tools.

Regulatory Implications

As a company in the medical device sector, BioSig Technologies is subject to significant regulatory scrutiny. Compliance with FDA regulations and other health-related standards is critical for product development, approval, and market access. Any changes in regulatory frameworks could impact the company's operations and product timelines.

What Investors Should Do

1. Vote your shares: Shareholders are strongly encouraged to vote via the Internet, telephone, or by returning a proxy card to ensure a quorum is met for the Special Meeting on September 5, 2025.
2. Review proxy materials: Familiarize yourself with the details provided in the DEF 14A filing regarding the purpose of the Special Meeting and any proposals to be voted upon.

Key Dates

• 2025-09-05: Special Meeting of Stockholders — Shareholders will vote on matters presented by the company, and their participation is crucial for establishing a quorum.
• 2025-08-04: Filing of Definitive Proxy Statement (DEF 14A) — This document officially notifies shareholders of the special meeting and provides details on how to vote.

Glossary

DEF 14A

A Definitive Proxy Statement filed with the SEC that provides shareholders with information about matters to be voted on at a company's annual or special meeting. (This is the primary document filed by BioSig Technologies, Inc. to communicate with shareholders regarding the upcoming special meeting.)

Quorum

The minimum number of shareholders required to be present (in person or by proxy) at a meeting for the meeting to be valid and for business to be transacted. (The company emphasizes the importance of shareholder votes to ensure a quorum is met for the Special Meeting.)

Proxy Card

A legal document that allows a shareholder to grant another person (usually a company representative) the authority to vote their shares on their behalf. (Shareholders are instructed to use the proxy card, or vote via internet/telephone, to ensure their vote is counted.)

Year-Over-Year Comparison

This DEF 14A filing is primarily a procedural document for a Special Meeting and does not contain comparative financial data or operational updates typically found in annual reports (10-K) or quarterly reports (10-Q). Therefore, a direct comparison of key metrics like revenue growth or margin changes to a previous filing is not possible with this document alone.

Filing Details

This Form DEF 14A (Form DEF 14A) was filed with the SEC on August 4, 2025 by Henry McPhie regarding BioSig Technologies, Inc. (STEX).

View full filing on EDGAR

View Full Filing

View this DEF 14A filing on SEC EDGAR